L3VLUP
ProSign in

SNDX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SNDXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SNDX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterSNDXJNJ
Q3 20201 holders, $4.1m30 holders, $26.2bn
Q4 20207 holders, $64m32 holders, $26.6bn
Q1 20212 holders, $34m31 holders, $25.3bn
Q2 20211 holders, $3.6m37 holders, $25.6bn
Q3 20211 holders, $11m40 holders, $24.1bn
Q4 20211 holders, $6.8m33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 2022none listed holders, n.a.33 holders, $26.9bn
Q3 20222 holders, $20m36 holders, $25.4bn
Q4 20223 holders, $235m35 holders, $27.6bn
Q1 20232 holders, $159m42 holders, $24.5bn
Q2 20235 holders, $209m38 holders, $25.0bn
Q3 20234 holders, $160m37 holders, $18.9bn
Q4 20237 holders, $322m31 holders, $19.0bn
Q1 20249 holders, $362m32 holders, $19.7bn
Q2 20248 holders, $322m35 holders, $20.4bn
Q3 20246 holders, $117m28 holders, $22.3bn
Q4 20243 holders, $50m37 holders, $20.4bn
Q1 20254 holders, $76m32 holders, $20.5bn
Q2 20253 holders, $38m31 holders, $18.4bn
Q3 20253 holders, $89m32 holders, $23.7bn
Q4 20256 holders, $165m29 holders, $27.8bn
Q1 20266 holders, $96m34 holders, $35.6bn
Q2 20263 holders, $36m33 holders, $39.1bn
SNDX

Syndax Pharmaceuticals Inc

Holders
6
Reported value
$117m
Buyers
3
Sellers
2

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
28
Reported value
$22.3bn
Buyers
13
Sellers
16

Breadth -3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SNDX (2)

Farallon Capital Management LLC, Point72 Asset Management LP

Only JNJ (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Walleye Capital LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →